PharVision Advisers’s Carter's CRI Stock Holding History

PharVision Advisers’s Portfolio CRI Stock Details CRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-7,772	Closed	-$234K	–	679
2025 Q2	$234K	Buy	+7,772	New	+$263K	0.34%	159

Other funds holding CRI

RWWM Inc Rocklin, California $1.35B AUM 9.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PharVision Advisers's CRI Position: Q3 2025 in Review

PharVision Advisers sold out of Carter's (CRI) in Q3 2025, closing a stake of 7,772 shares — an estimated $234K sold.

PharVision Advisers first reported a position in CRI in Q2 2025 and held it in 1 quarter. The position peaked at $234K in Q2 2025. 248 funds tracked by Wall St. Rank hold CRI as of Q3 2025.

PharVision Advisers reported no remaining Carter's position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 7,772 Carter's shares in Q3 2025, an estimated $234K.
PharVision Advisers first reported a position in Carter's in Q2 2025 and held it in 1 quarter.
PharVision Advisers's Carter's position peaked at $234K in Q2 2025.
248 funds tracked by Wall St. Rank held Carter's as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.